[go: up one dir, main page]

BRPI0718509A2 - compostos orgânicos heterocíclicos - Google Patents

compostos orgânicos heterocíclicos

Info

Publication number
BRPI0718509A2
BRPI0718509A2 BRPI0718509A BRPI0718509A BRPI0718509A2 BR PI0718509 A2 BRPI0718509 A2 BR PI0718509A2 BR PI0718509 A BRPI0718509 A BR PI0718509A BR PI0718509 A BRPI0718509 A BR PI0718509A BR PI0718509 A2 BRPI0718509 A2 BR PI0718509A2
Authority
BR
Brazil
Prior art keywords
organic compounds
heterocyclic organic
heterocyclic
compounds
organic
Prior art date
Application number
BRPI0718509A
Other languages
English (en)
Inventor
Jianmin Fu
Natalia Pokrovskaia
Natalie Dales
Rajender Kamboj
Serguei Sviridov
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of BRPI0718509A2 publication Critical patent/BRPI0718509A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0718509A 2006-09-22 2007-09-19 compostos orgânicos heterocíclicos BRPI0718509A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82662706P 2006-09-22 2006-09-22
PCT/US2007/078854 WO2008036715A1 (en) 2006-09-22 2007-09-19 Heterocyclic organic compounds

Publications (1)

Publication Number Publication Date
BRPI0718509A2 true BRPI0718509A2 (pt) 2015-09-29

Family

ID=38962856

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718509A BRPI0718509A2 (pt) 2006-09-22 2007-09-19 compostos orgânicos heterocíclicos

Country Status (11)

Country Link
US (1) US8236835B2 (pt)
EP (1) EP2066664A1 (pt)
JP (1) JP5351025B2 (pt)
KR (1) KR20090053923A (pt)
CN (1) CN101516877B (pt)
AU (1) AU2007299870A1 (pt)
BR (1) BRPI0718509A2 (pt)
CA (1) CA2662574A1 (pt)
MX (1) MX2009003080A (pt)
RU (1) RU2009114857A (pt)
WO (1) WO2008036715A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063084B2 (en) * 2006-08-15 2011-11-22 Novartis Ag Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
EP2121671A1 (en) 2006-12-20 2009-11-25 Novartis AG 2-substituted 5-membered heterocycles as scd inhibitors
JP5486928B2 (ja) 2007-02-26 2014-05-07 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックウレアおよびカルバメートインヒビター
ATE554078T1 (de) 2007-07-26 2012-05-15 Vitae Pharmaceuticals Inc Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
CA2712500A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5734666B2 (ja) 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5507474B2 (ja) 2008-02-20 2014-05-28 ノバルティス アーゲー ステアロイル−ＣｏＡデサチュラーゼのヘテロ環式阻害剤
US8242111B2 (en) 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CA2722427A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
PL2324018T3 (pl) 2008-07-25 2014-02-28 Boehringer Ingelheim Int Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
AU2010215035B2 (en) 2009-02-17 2014-06-12 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
JP5749263B2 (ja) 2009-07-01 2015-07-15 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
US8383643B2 (en) 2009-07-28 2013-02-26 Merck Canada Inc. Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
CN102574841A (zh) * 2009-10-01 2012-07-11 诺瓦提斯公司 调节硬脂酰-coa去饱和酶的吡唑衍生物
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
CN103179960A (zh) 2010-11-02 2013-06-26 贝林格尔.英格海姆国际有限公司 治疗代谢疾病的药物组合
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
BR112014029365A2 (pt) 2012-05-22 2017-06-27 Hoffmann La Roche inibidores seletivos de células indiferenciadas
SG11201900975XA (en) * 2016-08-24 2019-03-28 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CN108003086B (zh) * 2017-11-15 2020-08-14 宁波大学 一种3-胺基-2-吲哚酮类化合物的制备方法
EP3768269B1 (en) 2018-03-23 2025-08-20 Janssen Pharmaceutica NV Compounds and uses thereof
IL280639B (en) 2018-09-17 2022-07-01 Yungjin Pharmaceutical Co Ltd History of thiazoles and their pharmaceutically acceptable salts
AU2020212034A1 (en) 2019-01-24 2021-09-16 Janssen Pharmaceutica Nv Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056208A (en) * 1933-01-21 1936-10-06 Earl B Putt Acetyl-salicylic acid composition
FR2123206A1 (en) * 1971-01-29 1972-09-08 Anvar Thiazolyl-pyrrolidinones - as analgesics, sedatives barbiturate-potentiators
US4659726A (en) 1984-04-19 1987-04-21 Kanebo, Ltd. Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
JPH02160783A (ja) * 1988-12-15 1990-06-20 Nippon Tokushu Noyaku Seizo Kk ３，４−ジメチル−ピロリジン誘導体及び除草剤
JPH04247076A (ja) 1991-02-01 1992-09-03 Canon Inc 液晶性化合物、これを含む液晶組成物、およびその使用方法、それを使用した液晶素子、表示装置
IT1254199B (it) 1992-02-06 1995-09-14 Ministero Dell Uni E Della Tiazolilpirroli ad attivita' fungicida
US5254576A (en) 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
AU696084B2 (en) * 1994-06-02 1998-09-03 Zeneca Limited Substituted pyrrolidone, thiazolidones or oxazolidones as herbicides
IT1271026B (it) * 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
GB9510744D0 (en) * 1995-05-26 1995-07-19 Zeneca Ltd Chemical process
AU7453498A (en) 1997-05-30 1998-12-30 Takeda Chemical Industries Ltd. Sulfonamide derivatives, their production and use
JP2002521408A (ja) 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション 化合物および方法
WO2000033836A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation 5-membered heterocycles for the treatment of human diseases involving modulators of selectins
AU3517700A (en) 1999-03-15 2000-10-04 Abbott Laboratories 6-o-substituted macrolides having antibacterial activity
US6054435A (en) 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
IL155093A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases
ES2275621T3 (es) 2000-12-21 2007-06-16 Glaxo Group Limited Antibioticos macrolidos.
DK1363705T3 (da) * 2001-02-02 2012-09-24 Bristol Myers Squibb Co Sammensætning og antiviral aktivitet i substituerede azaindoloxoeddikesurpiperazin-derivater
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
DK2272813T3 (en) * 2001-04-24 2017-02-27 Massachusetts Inst Of Tech (Mit) COPPER CATALYST CREATION OF CARBON OXYGEN COMPOUNDS
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
ES2339107T3 (es) 2001-10-01 2010-05-17 Bristol-Myers Squibb Company Compuestos de espiro hidantoina utiles como agentes anti-inflamatorios.
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
GB0208579D0 (en) 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7211672B2 (en) 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
TW200416221A (en) * 2002-10-30 2004-09-01 Vertex Pharma Compositions useful as inhibitors of ROCK and other protein kinases
EP1601657A1 (en) 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazole modulators of atp-binding cassette transporters
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
JP2006522744A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
CN100441185C (zh) 2003-04-30 2008-12-10 麦克弗罗斯特加拿大有限公司 8-(3-联芳基)苯基喹啉磷酸二酯酶-4抑制剂
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CN1618796A (zh) 2003-11-21 2005-05-25 吉林省药物研究所 4，5－二取代－2－（1－取代－1h－吡咯－2－基）－噻唑衍生物
NZ551468A (en) 2003-12-24 2010-05-28 Biota Scient Management Polycyclic agents for the treatment of respiratory syncytial virus infections
GB0402496D0 (en) 2004-02-04 2004-03-10 Argenta Discovery Ltd Novel compounds
JP4853284B2 (ja) 2004-03-05 2012-01-11 大正製薬株式会社 チアゾール誘導体
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
GB0406280D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Chemical compounds
GB0406279D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
RU2006138603A (ru) 2004-04-07 2008-05-20 Милленниум Фармасьютикалз, Инк. (Us) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2005105065A2 (en) 2004-05-05 2005-11-10 Renopharm Ltd. Thiazole-based nitric oxide donors for treating inflammatory bowel diseases
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7585859B2 (en) 2004-05-06 2009-09-08 Plexxikon, Inc. PDE4B inhibitors and uses therefor
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
SG155222A1 (en) 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7767677B2 (en) * 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AU2005286793A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US20080312435A1 (en) 2004-11-15 2008-12-18 Taisho Pharmaceutical Co., Ltd. Imine Compound
CN1834095B (zh) 2005-03-18 2011-04-20 中国科学院上海药物研究所 一类非核苷类抗病毒抑制剂及其制备方法和用途
BRPI0608910A2 (pt) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
RS54876B1 (sr) 2005-05-10 2016-10-31 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
JPWO2006137527A1 (ja) 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
ES2643340T3 (es) 2005-08-02 2017-11-22 Kyowa Hakko Kirin Co., Ltd. Agentes para tratar y/o prevenir trastornos del sueño
JP2007126454A (ja) 2005-10-06 2007-05-24 Taisho Pharmaceut Co Ltd アニリド誘導体
WO2007087429A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses

Also Published As

Publication number Publication date
KR20090053923A (ko) 2009-05-28
US8236835B2 (en) 2012-08-07
WO2008036715A1 (en) 2008-03-27
MX2009003080A (es) 2009-04-02
JP2010504348A (ja) 2010-02-12
JP5351025B2 (ja) 2013-11-27
RU2009114857A (ru) 2010-10-27
CA2662574A1 (en) 2008-03-27
CN101516877B (zh) 2013-09-11
AU2007299870A1 (en) 2008-03-27
US20100029718A1 (en) 2010-02-04
EP2066664A1 (en) 2009-06-10
CN101516877A (zh) 2009-08-26

Similar Documents

Publication Publication Date Title
BRPI0718509A2 (pt) compostos orgânicos heterocíclicos
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
BRPI0718874A2 (pt) Compostos orgânicos
NO20084803L (no) organiske forbindelser
BRPI0718478A2 (pt) Compostos orgânicos
DK2240490T3 (da) Organiske forbindelser
BRPI0817434A2 (pt) Composto orgânicos
BRPI0811562A2 (pt) Compostos orgânicos
BRPI0712902A2 (pt) compostos orgânicos
DK1919907T3 (da) Heterocyklisk forbindelse
BRPI0922351A2 (pt) compostos orgânicos
BRPI0922700A2 (pt) Compostos orgânicos
BRPI0922808A2 (pt) compostos orgânicos
BRPI0922348A2 (pt) Compostos orgânicos
BRPI0922131A2 (pt) Compostos orgânicos
BRPI0922809A2 (pt) compostos orgânicos
BRPI0913966A2 (pt) compostos orgânicos
BRPI0914698A2 (pt) compostos orgânicos
BRPI0909417A2 (pt) compostos orgânicos
BRPI0915018A2 (pt) compostos orgânicos
DK2310359T3 (da) Organiske forbindelser
BRPI0821401A2 (pt) Compostos orgânicos
BRPI0917574A2 (pt) compostos orgânicos
BRPI0921826A2 (pt) compostos orgânicos
ATE524477T1 (de) Aziridinylepothilonverbindungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.